1. Smoking does not Alter the Therapy Response to Systemic Anti-psoriatic Therapies: A Two-country, Multi-centre, Prospective, Non-interventional Study
- Author
-
Peter Itin, Mathias Drach, Matthias Augustin, Lars E. French, C. Sorbe, Markus Streit, Florian Anzengruber, Kristian Reich, Ulrich Mrowietz, Julia-Tatjana Maul, Diamant Thaçi, Alexander A. Navarini, Marc Alexander Radtke, Nikhil Yawalkar, University of Zurich, and Navarini, Alexander A
- Subjects
Male ,Time Factors ,apremilast ,Severity of Illness Index ,tobacco ,0302 clinical medicine ,Germany ,adalimumab ,lcsh:Dermatology ,Prospective Studies ,Registries ,610 Medicine & health ,secukinumab ,Remission Induction ,Smoking ,10177 Dermatology Clinic ,Dermatology Life Quality Index ,psoriasis ,General Medicine ,Middle Aged ,Treatment Outcome ,030220 oncology & carcinogenesis ,fumaric acid esters ,Female ,030211 gastroenterology & hepatology ,acitretin ,Switzerland ,medicine.drug ,Adult ,medicine.medical_specialty ,Dermatology ,methotrexate ,ustekinumab ,Acitretin ,ciclosporin ,2708 Dermatology ,03 medical and health sciences ,Psoriasis Area and Severity Index ,Internal medicine ,Psoriasis ,Ustekinumab ,medicine ,Adalimumab ,Humans ,business.industry ,treatment response ,lcsh:RL1-803 ,medicine.disease ,Infliximab ,Quality of Life ,Dermatologic Agents ,Apremilast ,business ,infliximab ,etanercept ,nicotine - Abstract
Psoriasis can involve the skin, joints, nails and cardiovascular system and result in a significant impairment in quality of life. Studies have shown a lower response rate to systemic anti-psoriatic therapies in smokers, and smoking is a trigger factor for psoriasis. The aim of this study was therefore to analyse the response to systemic therapies for psoriasis, with a focus on smoking. Prospectively collected data from patients with moderate to severe psoriasis included in the national psoriasis registries for Germany and Switzerland (PsoBest and SDNTT) were analysed. Therapy response was defined as reaching a Psoriasis Area and Severity Index (PASI) reduction of 75%, PASI ≤ 3 or Dermatology Life Quality Index (DLQI) ≤ 1. Out of 5,346 patients included in these registries, 1,264 met the inclusion criteria for this study. In the smoking group, 715 (60.6%) reached therapy response at month 3, compared with 358 (63.7%) in the non-smoking group (p ≤ 0.269), 659 (74.1%) vs. 330 (77%) reached therapy response at month 6 (p ≤ 0.097), and 504 (76.6%) vs. 272 (79.0%) at month 12 (p ≤ 0.611). Therefore, these data do not show that smoking affects the response rate of anti-psoriatic therapy after 3, 6 and 12 months.
- Published
- 2019
- Full Text
- View/download PDF